RECRUITINGINTERVENTIONAL

Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Eye Pressure in Non-Caucasian Patients With Open Angle Glaucoma

Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Intraocular Pressure in Non-Caucasian Open Angle Glaucoma Patients

About This Trial

The goal of this clinical trial is to to evaluate how well Direct Selective Laser Trabeculoplasty (DSLT) lowers eye pressure in eyes of adult, non-Caucasian participants with primary open angle glaucoma. The main question it aims to answer is: What is the washed out eye pressure (eye pressure when not on any glaucoma medications) of participants 6 months after the Direct Selective Laser Trabeculoplasty (DSLT) procedure compared to the washed out eye pressure of participants prior to the DSLT procedure. Participants will: Undergo the DSLT procedure in one or both eyes and visit the clinic 1 month, 3 months, and 6 months after the procedure to have their vision and eye pressure measured.

Who May Be Eligible (Plain English)

Who May Qualify: - Adult patients of Black African descent scheduled to undergo DSLT treatment in one or both eyes. - Diagnosis of mild to moderate primary open angle glaucoma (POAG). - Mild to moderate POAG will be defined as Stage 2 or better of the Hodapp-Anderson-Parrish glaucoma staging system. - Treatment naive or washed out IOP at time 0 ranging from ≥ 21 through 32 mm Hg. Who Should NOT Join This Trial: - Screened patients who were on IOP-lowering medications who did not successfully complete medication washout at the time of the procedure (time 0). - Previous glaucoma surgeries/interventions: - Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt). - Secondary glaucoma: - Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases. - Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator. - Subjects who are pregnant, breast-feeding, or intend to become pregnant during the study period as determined by verbal inquiry. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Adult patients of Black African descent scheduled to undergo DSLT treatment in one or both eyes. * Diagnosis of mild to moderate primary open angle glaucoma (POAG). * Mild to moderate POAG will be defined as Stage 2 or better of the Hodapp-Anderson-Parrish glaucoma staging system. * Treatment naive or washed out IOP at time 0 ranging from ≥ 21 through 32 mm Hg. Exclusion Criteria: * Screened patients who were on IOP-lowering medications who did not successfully complete medication washout at the time of the procedure (time 0). * Previous glaucoma surgeries/interventions: * Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt). * Secondary glaucoma: * Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases. * Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator. * Subjects who are pregnant, breast-feeding, or intend to become pregnant during the study period as determined by verbal inquiry.

Treatments Being Tested

DEVICE

Direct Selective Laser Trabeculoplasty

DSLT using the Belkin Vision Eagle Device

Locations (1)

Select Eye Care

Elkridge, Maryland, United States